South Korean pharmaceutical company Celterion (Seo Jung-Jin) intends to apply for emergency use permission to treat the emerging corona virus, which it is developing from the Ministry of Food and Drug Safety next month .
According to Arabia Net, the company had announced CT-P59, which is a treatment with monoclonal antibodies against Covid-19, and shortens the recovery time of patients without reporting No side effects.
The treatment is currently undergoing the second phase of clinical trials, after the successful completion of the first phase on healthy volunteers who did not have the virus, according to the Korean Yonhap Agency.
She also said that the drug kills the Coronavirus within 4-5 days, which effectively protects patients with mild symptoms from developing a serious condition.
>
The Chairman of the Board of Directors of Celterion Group said: Celterion is currently completing the second phase of clinical trials for antibody therapy, and we will do our best to obtain conditional permission from the Ministry of Safety Food and medicine by the end of the year.
